Expert Ratings For Caribou Biosciences
Portfolio Pulse from Benzinga Insights
Caribou Biosciences (NASDAQ:CRBU) received mixed ratings from 4 analysts over the past three months, with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target is $21.5, with a high of $24.00 and a low of $19.00. The company's financials show a decline in revenue growth and challenges in ROA, but strong net margins and prudent debt management.
May 16, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Caribou Biosciences received mixed ratings from analysts, with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target is $21.5, down 6.52% from the prior average. Financials show a decline in revenue growth but strong net margins and prudent debt management.
The mixed analyst ratings and the slight decline in the average price target suggest a neutral short-term impact on the stock price. While the company's financials show some challenges, strong net margins and prudent debt management provide a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100